Literature DB >> 15858020

Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.

Mengji Lu1, Masanori Isogawa, Yang Xu, Gero Hilken.   

Abstract

A number of options are available to modify and improve DNA vaccines. An interesting approach to improve DNA vaccines is to fuse bioactive domains, like cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4), to an antigen. Such fusion antigens are expressed in vivo and directed to immune cells by the specific bioactive domain and therefore possess great potential to induce and modulate antigen-specific immune responses. In the present study, we tested this new approach for immunomodulation against hepadnavirus infection in the woodchuck model. Plasmids expressing the nucleocapsid protein (WHcAg) and e antigen (WHeAg) of woodchuck hepatitis virus (WHV) alone or in fusion to the extracellular domain of woodchuck CTLA-4 and CD28 were constructed. Immunizations of mice with plasmids expressing WHcAg or WHeAg led to a specific immunoglobulin G2a (IgG2a)-dominant antibody response. In contrast, fusions of WHcAg to CTLA-4 and CD28 induced a specific antibody response with comparable levels of IgG1 and IgG2a. Furthermore, the specific IgG1 response to WHcAg/WHeAg developed immediately after a single immunization with the CTLA-4-WHcAg fusion. Woodchucks were immunized with plasmids expressing WHeAg or the CTLA-4-WHcAg fusion and subsequently challenged with WHV. CTLA-4-WHcAg showed an improved efficacy in induction of protective immune responses to WHV. In particular, the anti-WHsAg antibody response developed earlier after challenge in woodchucks that received immunizations with CTLA-4-WHcAg, consistent with the hypothesis that anti-WHs response is dependent on a Th cell response to WHcAg. In conclusion, the use of fusion genes represents a generally applicable strategy to improve DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858020      PMCID: PMC1091665          DOI: 10.1128/JVI.79.10.6368-6376.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Gene vaccines.

Authors:  Indresh K Srivastava; Margaret A Liu
Journal:  Ann Intern Med       Date:  2003-04-01       Impact factor: 25.391

2.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES.

Authors:  Seung Jo Kim; Dongchul Suh; Sang Eun Park; Jeong-Sook Park; Hyang-Min Byun; Chan Lee; Sun Young Lee; Inho Kim; Yu-Kyoung Oh
Journal:  Virology       Date:  2003-09-15       Impact factor: 3.616

4.  Gene gun immunization in a preclinical model is enhanced by B7 targeting.

Authors:  Mary Tachedjian; Jeff S Boyle; Andrew M Lew; Biserka Horvatic; Jean-Pierre Y Scheerlinck; Jan M Tennent; Marion E Andrew
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

5.  Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.

Authors:  D R Milich; A McLachlan; G B Thornton; J L Hughes
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

6.  Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen.

Authors:  P J Cote; M Shapiro; R E Engle; H Popper; R H Purcell; J L Gerin
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

7.  Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES.

Authors:  S J Kim; C Lee; S Y Lee; I Kim; J S Park; T Sasagawa; J J Ko; S E Park; Y-K Oh
Journal:  Gene Ther       Date:  2003-08       Impact factor: 5.250

8.  Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens.

Authors:  Mengji Lu; Ruediger Klaes; Stephan Menne; Wolfram Gerlich; Benno Stahl; Hans-Peter Dienes; Uta Drebber; Michael Roggendorf
Journal:  J Hepatol       Date:  2003-09       Impact factor: 25.083

9.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report.

Authors:  W Szmuness; C E Stevens; E A Zang; E J Harley; A Kellner
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Molecular characterization of CD28 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) of woodchuck (Marmota monax).

Authors:  D Yang; M Roggendorf; M Lu
Journal:  Tissue Antigens       Date:  2003-09
View more
  17 in total

1.  Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen.

Authors:  Wei Zhang; Sheng-Fu Dong; Shu-Hui Sun; Yuan Wang; Guang-Di Li; Di Qu
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 2.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.

Authors:  Anna D Kosinska; Lena Johrden; Ejuan Zhang; Melanie Fiedler; Anja Mayer; Oliver Wildner; Mengji Lu; Michael Roggendorf
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

4.  Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.

Authors:  Katherine H Liu; Mary A Ascenzi; Christine A Bellezza; Abraham J Bezuidenhout; Paul J Cote; Gloria Gonzalez-Aseguinolaza; Drew Hannaman; Alain Luxembourg; Claire F Evans; Bud C Tennant; Stephan Menne
Journal:  J Virol       Date:  2011-03-09       Impact factor: 5.103

5.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

6.  beta-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen.

Authors:  Jing Wang; Shengfu Dong; Chunhong Liu; Wei Wang; Shuhui Sun; Jianxin Gu; Yuan Wang; Diana Boraschi; Di Qu
Journal:  J Biomed Biotechnol       Date:  2010-06-10

7.  Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.

Authors:  Mengji Lu; Xin Yao; Yang Xu; Heike Lorenz; Uta Dahmen; Haidong Chi; Olaf Dirsch; Thekla Kemper; Lifang He; Dieter Glebe; Wolfram H Gerlich; Yumei Wen; Michael Roggendorf
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

8.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

9.  DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.

Authors:  Ying Yin; Chunchen Wu; Jingjiao Song; Junzhong Wang; Ejuan Zhang; Hongyan Liu; Dongliang Yang; Xinwen Chen; Mengji Lu; Yang Xu
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

10.  Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.

Authors:  Anna D Kosinska; Ejuan Zhang; Lena Johrden; Jia Liu; Pia L Seiz; Xiaoyong Zhang; Zhiyong Ma; Thekla Kemper; Melanie Fiedler; Dieter Glebe; Oliver Wildner; Ulf Dittmer; Mengji Lu; Michael Roggendorf
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.